Biocompatibles to start clinical trial of Irinotecan bead in colorectal cancer

By Lisa Kerner

Erie, Pa., March 9 - Biocompatibles International plc announced the start of a clinical trial for the evaluation of an Irinotecan Drug Eluting Bead in the treatment of colorectal cancer metastases in the liver.

The first patient has been treated at the Johann Wolfgang Goethe-University, Frankfurt using, for the first time, a bead containing the drug Irinotecan, according to a company news release.

This trial complements the Precision family of trials evaluating beads that contain Doxorubicin in the treatment of primary liver cancer.

The Irinotecan Drug Eluting Beads will be delivered, via a catheter through the hepatic artery, in patients with unresectable tumors who have failed two previous chemotherapy regimes, the company said.

The endpoints of the trial are safety and tumor response at six months.

Biocompatibles said a preclinical evaluation of the Irinotecan Eluting Bead is in progress and the company expects to present data at the annual meeting of the American Association for Cancer Research next month.

According to the release, there are more than 400,000 new cases of colorectal cancer in the United States and European Union each year, of which 50% will develop liver metastases within five years of diagnosis.

Biocompatibles is a medical technology company focused on drug device combination products for use in oncology and cardiology. The company is based in Surrey, U.K.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.